Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).
The authors investigated the relationship between statin use and the risk of stroke in the Heart and Estrogen-Progestin Replacement Study (HERS). Despite large reductions in relative risk point estimates, statin use was not associated with differences in the risks of all fatal stroke (relative hazard [RH] 0.52, 95% CI 0.23 to 1.18, p = 0.12), fatal ischemic stroke (RH 0.51, 95% CI 0.18 to 1.45, p = 0.21), fatal hemorrhagic stroke (RH 0.18, 95% CI 0.02 to 1.46, p = 0.11), or TIA (RH 1.32, 95% CI 0.84 to 2.09, p = 0.23).
Bushnell
C D
CD
Department of Medicine, Duke Center for Cerebrovascular Disease, Division of Cardiology Durham, NC, USA. Cheryl.Bushnell@duke.edu
Newby
L K
LK
Goldstein
L B
LB
Lin
F
F
Yaffe
K
K
Simon
J A
JA
D000368:Aged; D015331:Cohort Studies; D003327:Coronary Disease / Q000188:drug therapy; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D002546:Ischemic Attack, Transient / Q000453:epidemiology*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012306:Risk; D020521:Stroke / Q000401:mortality* / Q000517:prevention & control; D016019:Survival Analysis
D004966:Estrogens, Conjugated (USP); D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017258:Medroxyprogesterone Acetate